BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
40.16 EUR
-0.83 (-2.01%)
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 50 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM may be a bit undervalued, certainly considering the very reasonable score on growth Finally BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 5.33%, BRM perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
With an excellent Return On Equity value of 28.96%, BRM belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 15.09%, BRM belongs to the top of the industry, outperforming 82.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 14.78%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(15.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Profit Margin of 10.58%. This is comparable to the rest of the industry: BRM outperforms 48.00% of its industry peers.
The Operating Margin of BRM (30.27%) is better than 84.00% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
The Gross Margin of BRM (73.92%) is better than 70.00% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BRM is creating some value.
Compared to 1 year ago, BRM has less shares outstanding
The number of shares outstanding for BRM has been reduced compared to 5 years ago.
Compared to 1 year ago, BRM has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.06 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.06, BRM is doing worse than 60.00% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.37, which is a good value as it means it would take BRM, 3.37 years of fcf income to pay off all of its debts.
BRM has a Debt to FCF ratio of 3.37. This is in the better half of the industry: BRM outperforms 62.00% of its industry peers.
BRM has a Debt/Equity ratio of 2.56. This is a high value indicating a heavy dependency on external financing.
BRM has a Debt to Equity ratio of 2.56. This is amonst the worse of the industry: BRM underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.06 |
ROIC/WACC1.7
WACC8.88%
2.3 Liquidity
A Current Ratio of 1.21 indicates that BRM should not have too much problems paying its short term obligations.
BRM has a Current ratio of 1.21. This is in the lower half of the industry: BRM underperforms 62.00% of its industry peers.
A Quick Ratio of 1.11 indicates that BRM should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.11, BRM is doing good in the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 391.24% over the past year.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 2.57%.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.14% yearly.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.00% yearly.
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue Next Year-1.22%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.48%
Revenue Next 5Y-5%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.00, which indicates a rather cheap valuation of BRM.
92.00% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
BRM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.30.
BRM is valuated cheaply with a Price/Forward Earnings ratio of 7.74.
Based on the Price/Forward Earnings ratio, BRM is valued cheaply inside the industry as 88.00% of the companies are valued more expensively.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7 | ||
| Fwd PE | 7.74 |
4.2 Price Multiples
92.00% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 94.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.57 | ||
| EV/EBITDA | 6.22 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.40% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y130.91%
EPS Next 3Y73.4%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.22%, BRM is a good candidate for dividend investing.
BRM's Dividend Yield is rather good when compared to the industry average which is at 3.04. BRM pays more dividend than 92.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.22% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
98.12% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
FRA:BRM (9/12/2025, 7:00:00 PM)
40.16
-0.83 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners84.14%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap81.74B
Analysts67.27
Price Target44.45 (10.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.22% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-2.1%
PT rev (3m)-9.17%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-5.33%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)2.16%
Revenue NY rev (3m)2.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7 | ||
| Fwd PE | 7.74 | ||
| P/S | 2.01 | ||
| P/FCF | 6.57 | ||
| P/OCF | 6.02 | ||
| P/B | 5.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.22 |
EPS(TTM)5.74
EY14.29%
EPS(NY)5.19
Fwd EY12.92%
FCF(TTM)6.11
FCFY15.22%
OCF(TTM)6.67
OCFY16.6%
SpS20
BVpS7.31
TBVpS-10.78
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-16.88%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.06 |
F-Score7
WACC8.88%
ROIC/WACC1.7
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.22%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.48%
Revenue Next 5Y-5%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year268.01%
EBIT Next 3Y49.33%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%